| Andrea Brock, MD | |
|
3000 N Triumph Blvd Ste 330, Lehi, UT 84043-4999 | |
| (385) 345-3560 | |
| (385) 351-3647 |
| Full Name | Andrea Brock |
|---|---|
| Gender | Female |
| Speciality | Neurosurgery |
| Experience | 11 Years |
| Location | 3000 N Triumph Blvd Ste 330, Lehi, Utah |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912341009 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 9148362-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Utah Valley Hospital | Provo, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
Heart disease patients 65 and older who receive stents coated with medicine to prevent blockages are more likely to survive and less likely to suffer a heart attack than people fitted with stents not coated with medication, according to a new study supported by HHS' Agency for Healthcare Research and Quality and the American College of Cardiology's National Cardiovascular Data Registry.
Arrowhead Research Corporation announced today that its portfolio company, Leonardo Biosystems, has received a $2.5 million grant from the Texas Emerging Technology Fund, a state fund established to accelerate commercialization of new technologies. Leonardo Biosystems, co-founded by prominent nanoscientist Dr. Mauro Ferrari, professor at the University of Texas, and Arrowhead's, CEO Dr. Christopher Anzalone, is engineering a multi-stage drug delivery platform to improve the effectiveness of drug therapy, particularly for cancer.
Why do certain gastrointestinal bacteria cause disease in some people but not others? What are the underlying mechanisms responsible for this? These questions are now being addressed by a new Emmy Noether Independent Junior Research Group at Charité - Universitätsmedizin Berlin.
Texas employers can learn about the signs and symptoms of drug impairment among workers at an inaugural program being held at Sam Houston State University (SHSU) June 14. The free, six-hour program will be available to all Texas employers after Sept. 1, 2011.
Researchers at The University of Texas MD Anderson Cancer Center have identified a biomarker living next door to the KLK3 gene that can predict which GS7 prostate cancer patients will have a more aggressive form of cancer.
› Verified 7 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629260880 PECOS PAC ID: 1850209420 Enrollment ID: O20031105000079 |
News Archive
Heart disease patients 65 and older who receive stents coated with medicine to prevent blockages are more likely to survive and less likely to suffer a heart attack than people fitted with stents not coated with medication, according to a new study supported by HHS' Agency for Healthcare Research and Quality and the American College of Cardiology's National Cardiovascular Data Registry.
Arrowhead Research Corporation announced today that its portfolio company, Leonardo Biosystems, has received a $2.5 million grant from the Texas Emerging Technology Fund, a state fund established to accelerate commercialization of new technologies. Leonardo Biosystems, co-founded by prominent nanoscientist Dr. Mauro Ferrari, professor at the University of Texas, and Arrowhead's, CEO Dr. Christopher Anzalone, is engineering a multi-stage drug delivery platform to improve the effectiveness of drug therapy, particularly for cancer.
Why do certain gastrointestinal bacteria cause disease in some people but not others? What are the underlying mechanisms responsible for this? These questions are now being addressed by a new Emmy Noether Independent Junior Research Group at Charité - Universitätsmedizin Berlin.
Texas employers can learn about the signs and symptoms of drug impairment among workers at an inaugural program being held at Sam Houston State University (SHSU) June 14. The free, six-hour program will be available to all Texas employers after Sept. 1, 2011.
Researchers at The University of Texas MD Anderson Cancer Center have identified a biomarker living next door to the KLK3 gene that can predict which GS7 prostate cancer patients will have a more aggressive form of cancer.
› Verified 7 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
Heart disease patients 65 and older who receive stents coated with medicine to prevent blockages are more likely to survive and less likely to suffer a heart attack than people fitted with stents not coated with medication, according to a new study supported by HHS' Agency for Healthcare Research and Quality and the American College of Cardiology's National Cardiovascular Data Registry.
Arrowhead Research Corporation announced today that its portfolio company, Leonardo Biosystems, has received a $2.5 million grant from the Texas Emerging Technology Fund, a state fund established to accelerate commercialization of new technologies. Leonardo Biosystems, co-founded by prominent nanoscientist Dr. Mauro Ferrari, professor at the University of Texas, and Arrowhead's, CEO Dr. Christopher Anzalone, is engineering a multi-stage drug delivery platform to improve the effectiveness of drug therapy, particularly for cancer.
Why do certain gastrointestinal bacteria cause disease in some people but not others? What are the underlying mechanisms responsible for this? These questions are now being addressed by a new Emmy Noether Independent Junior Research Group at Charité - Universitätsmedizin Berlin.
Texas employers can learn about the signs and symptoms of drug impairment among workers at an inaugural program being held at Sam Houston State University (SHSU) June 14. The free, six-hour program will be available to all Texas employers after Sept. 1, 2011.
Researchers at The University of Texas MD Anderson Cancer Center have identified a biomarker living next door to the KLK3 gene that can predict which GS7 prostate cancer patients will have a more aggressive form of cancer.
› Verified 7 days ago
| Entity Name | Summit Brain And Spine Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962045096 PECOS PAC ID: 2365877917 Enrollment ID: O20200109000290 |
News Archive
Heart disease patients 65 and older who receive stents coated with medicine to prevent blockages are more likely to survive and less likely to suffer a heart attack than people fitted with stents not coated with medication, according to a new study supported by HHS' Agency for Healthcare Research and Quality and the American College of Cardiology's National Cardiovascular Data Registry.
Arrowhead Research Corporation announced today that its portfolio company, Leonardo Biosystems, has received a $2.5 million grant from the Texas Emerging Technology Fund, a state fund established to accelerate commercialization of new technologies. Leonardo Biosystems, co-founded by prominent nanoscientist Dr. Mauro Ferrari, professor at the University of Texas, and Arrowhead's, CEO Dr. Christopher Anzalone, is engineering a multi-stage drug delivery platform to improve the effectiveness of drug therapy, particularly for cancer.
Why do certain gastrointestinal bacteria cause disease in some people but not others? What are the underlying mechanisms responsible for this? These questions are now being addressed by a new Emmy Noether Independent Junior Research Group at Charité - Universitätsmedizin Berlin.
Texas employers can learn about the signs and symptoms of drug impairment among workers at an inaugural program being held at Sam Houston State University (SHSU) June 14. The free, six-hour program will be available to all Texas employers after Sept. 1, 2011.
Researchers at The University of Texas MD Anderson Cancer Center have identified a biomarker living next door to the KLK3 gene that can predict which GS7 prostate cancer patients will have a more aggressive form of cancer.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Andrea Brock, MD 3000 N Triumph Blvd Ste 330, Lehi, UT 84043-4999 Ph: (385) 345-3560 | Andrea Brock, MD 3000 N Triumph Blvd Ste 330, Lehi, UT 84043-4999 Ph: (385) 345-3560 |
News Archive
Heart disease patients 65 and older who receive stents coated with medicine to prevent blockages are more likely to survive and less likely to suffer a heart attack than people fitted with stents not coated with medication, according to a new study supported by HHS' Agency for Healthcare Research and Quality and the American College of Cardiology's National Cardiovascular Data Registry.
Arrowhead Research Corporation announced today that its portfolio company, Leonardo Biosystems, has received a $2.5 million grant from the Texas Emerging Technology Fund, a state fund established to accelerate commercialization of new technologies. Leonardo Biosystems, co-founded by prominent nanoscientist Dr. Mauro Ferrari, professor at the University of Texas, and Arrowhead's, CEO Dr. Christopher Anzalone, is engineering a multi-stage drug delivery platform to improve the effectiveness of drug therapy, particularly for cancer.
Why do certain gastrointestinal bacteria cause disease in some people but not others? What are the underlying mechanisms responsible for this? These questions are now being addressed by a new Emmy Noether Independent Junior Research Group at Charité - Universitätsmedizin Berlin.
Texas employers can learn about the signs and symptoms of drug impairment among workers at an inaugural program being held at Sam Houston State University (SHSU) June 14. The free, six-hour program will be available to all Texas employers after Sept. 1, 2011.
Researchers at The University of Texas MD Anderson Cancer Center have identified a biomarker living next door to the KLK3 gene that can predict which GS7 prostate cancer patients will have a more aggressive form of cancer.
› Verified 7 days ago
Dr. Brian L Anderson, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 3000 N Triumph Blvd Ste 330, Lehi, UT 84043 Phone: 385-345-3560 |